Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.

Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.54 and traded as ...

Cellipont Bioservices and Secretome Therapeutics are set to enter a collaboration in the manufacture of the latter’s cellular therapy, STM-01. The collaboration will see Cellipont offering technology ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

A specially designed drug prevented laboratory mice from developing heart failure after heart attacks, according to new ...

Managing heart failure @home (MHF @home) is an approach that aims to support people to manage their heart failure condition and keep well at home. Remote monitoring, when clinically appropriate and ...